Oct. 10, 2024	A paper by visiting researcher Dr. Yohei Takahashi, first author, entitled "Antithrombin regulates neutrophil activities through the stimulation of C-type lectin family 1A" was published online on October 8th in the international journal Blood Vessels, Thrombosis & Hemostasis (Blood, VTH). In this study, the specific cell plasma membrane receptor involved in the anti-inflammatory action of antithrombin, a member of the plasma serine proteinase inhibitor (SERPIN) family, was explored, and C-type lectin family 1A (CLEC1A) was identified, along with specifically clarifying how the receptor stimulates and regulates the function of human neutrophils. The results of this research are expected to bring about new developments in plasma proteinology, and the contents were released in a Press Release from Okayama University.　NEW The news was also released from Science Japan (JPS). (11/27)
May. 30, 2024	We published a paper entitled “Anti-HMGB1 mAb therapy reduces epidural hematoma injury” by Gao S, Wang D, Liu K, Fu L, Gao Y, Takahashi Y, Yata M, Nishibori M. in the Special Issue of International Journal of Molecular Sciences.
Dec. 14-16, 2023	Prof. Nishibori attended the combined meeting of the 97th Japanese Pharmacological Society and the 44th Japanese Society of Clinical Pharmacology and Therapeutics and played a role of chair on a session of “Practical activities of drug development in academic fields.” Prof. Sakaguchi (Dept of Cell Biology), a collaborator, provided a speech entitled “Screening and identification method of specific receptors for multifunctional plasma proteins and its application for drug development” in the session.
Dec. 2, 2023	We attended the 40th Forum on Drug Research in Okayama (FDRO) .
Nov. 14-15, 2023	Prof. Nishibori attended in BIO-Europe 2023 online.
Sep. 14, 2023	Dr. Oinuma M. from AMED visited our lob to discuss the ongoing project “Target validation and the discovery of drug candidate based on clinical evidences” (PI: Prof. Nishibori).
Aug. 31, 2023	The patent application entitled “Agent for enhancing phagocytosis ability of neutrophils (JP7349862)” has been established.
Jul. 22, 2023	We attended the 39th Forum on Drug Research in Okayama (FDRO) .
Jun. 24, 2023	Dr. Takahashi participated in the 143th Kinki branch meeting of the Japanese pharmacological society in Nagoya and presented the research results entitled " The screening and identification of a specific receptor for a plasma protein, antithrombin".
May. 24-26, 2023	Prof. Nishibori participated in 9th European Stroke Organisation Conference held in Munich and presented the research results entitled "Humanized anti-HMGB1 monoclonal antibody therapy for marmoset intracerebral hemorrhage".
May. 21, 2023	Prof. Nishibori visited Prof. Michal Stros in Czech Academy of Sciences to discuss a common interest on HMGB1 study.
Apr. 26, 2023	We held a research meeting with the partitipating members on a theme ”Research on Development of New Drugs” supported by AMED.
Apr. 15, 2023	A grant application by Prof. Nishibori to Japan Agency for Medical Research and Development has been adopted in the project field of “Research on Development of New Drugs”.
Dec. 5, 2022	The study results on HMGB1 vascular endothelial cells and its relation to anaphylaxis was published in Sanyo Newspaper article.
Dec. 1, 2022	Prof. Nishibori presented a novel drug discovery seed ”A novel therapy for inflammatory diseases by 4-HNE monoclonal antibody” in a Special Symposium in the 96th Annual Meeting of the Japanese Pharmacological Society.
Nov. 8, 2022	We made a Press Release on “Histamine induced high mobility group box-1 release from vascular endothelial cells through H1 receptor” (doi.org/10.3389/fimmu.2022.930683).
Oct 12-14, 2022	Prof. Nishibori participated in BioJapan 2022.
Sep. 27, 2022	We made a Press Release on “Treatment of marmoset intracerebral hemorrhage with humanized anti-HMGB1 mAb.” in collaboration with Dr. Kenzo Takada (Evec Inc.).
Jul. 1, 2022	Dr. Shangze Gao (present address: Tsinghua University) presented " Histamine induced high mobility group box-1 release from vascular endothelial cells through H1 receptor " in 141th Japanese Pharmacological Society Meeting and obtain the Prize for the Young Investigator.
Jun. 7, 2022	We made a Press Release on “A novel biomarker of unresponsiveness to IVIG in Kawasaki Disease” in collaboration with Pediatric group (Prof. Tsukahara, Dr. Yashiro and Dr. Namba). (Reference: DOI: 10.1093/mr/roac040)
Apr. 1, 2022	A grant application by Prof. Nishibori to Health, Labour and Welfare Sciences Research Grants has been adopted in the project field of “Research on chronic pain”.
Mar. 18, 2022	Prof. Nishibori gave a invited lecture entitled "Systemic inflammation in sepsis and fundamental role of HMGB1" in The 49th Annual Meeting of the Japanese Society of Intensive Care Medicine.
Mar. 8, 2022	Prof. Nishibori was recommended as an Emeritus Member of Japanese Pharmacological Society.
Mar. 7, 2022	Prof. Nishibori presented a novel drug discovery seed ”Development of novel antibody-drug conjugates that target cancer vascular cells to promote anti-tumor activity” in a Special Symposium in the 95th Annual Meeting of the Japanese Pharmacological Society.
Feb. 7, 2022	Prof. Nishibori participated in matching seminar for seeds from college by TLO-KYOTO Ltd.
Jan. 25, 2022	We would like to express our sincere thanks to many participans in the Chugoku-Shikoku Sepsis Treatment WEB Lecture.
Jan. 20, 2022	Dr. Yasuhisa Izushi joined the Department as a visiting researcher.
Jan. 4, 2022	Dr. Youhei Takahashi joined the Department as a visiting researcher.
Nov. 1, 2021	Dr. Yasuko Tomono joined the Department as a visiting researcher.
Oct. 12-15, 2021	Prof. Nishibori participated in BioJapan 2021.
Oct, 2021	We have started Department of Translational Research and Drug Development.